Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clorotepine SCHEMBL29822559 | 1.00 | DRD2 (1.00) | DRD2HRH1HTR2CDRD4KCNK9 | |
| SCHEMBL23999963 | 0.91 | DRD2 (0.83) | DRD2HRH1HTR2CDRD4KCNK9 | |
| SCHEMBL30810194 | 0.91 | DRD2 (0.83) | DRD2HRH1HTR2CDRD4KCNK9 | |
| SCHEMBL18310354 | 0.90 | DRD2 (0.81) | DRD2HRH1HTR2CDRD4KCNK9 | |
| SCHEMBL3837897 | 0.86 | DRD2 (0.75) | DRD2HRH1HTR2CDRD4KCNK9 | |
| SCHEMBL29414105 | 0.86 | DRD2 (0.75) | DRD2HRH1HTR2CDRD4KCNK9 | |
| SCHEMBL11471578 | 0.86 | DRD2 (0.75) | DRD2HRH1HTR2CDRD4KCNK9 | |
| SCHEMBL10873797 | 0.85 | DRD2 (0.73) | DRD2HRH1HTR2CDRD4KCNK9 | |
| SCHEMBL30810181 | 0.84 | DRD2 (0.72) | DRD2HRH1HTR2CDRD4KCNK9 | |
| SCHEMBL11852333 | 0.84 | DRD2 (0.72) | DRD2HRH1HTR2CDRD4KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| US-20210228570-A1 | COMPOSITIONS AND METHODS FOR OPIOID OVERDOSE RESCUE | PURDUE PHARMA LP (US) | 2021-07-29 | — | — | US | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| WO-2018015915-A1 | A PARENTERAL CONTROLLED RELEASE COMPOSITION OF AN ATYPICAL ANTIPSYCHOTIC AGENT | CADILA HEALTHCARE LIMITED (IN) | 2018-01-25 | — | — | WO | claimed |
| CN-105879031-A | Anticancer-drug-free composition realizing synergistic treatment on tumor | 北京大学 | 2016-08-24 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060252749-A1 | Lacosamide for add-on therapy of psychosis | SRZ PROPERTIES, INC. (US) | 2006-11-09 | — | — | US | claimed |
| JP-8071293-A | — | — | None | — | — | JP | disclosed |
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2026-05-07 | — | — | US | disclosed |
| EP-4735441-A1 | PYRROLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF MENTAL ILLNESSES | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115188-A1 | METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116901-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2026-04-30 | — | — | US | disclosed |
| US-12606543-B2 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | MINDSET PHARMA INC. (CA) | 2026-04-21 | — | — | US | disclosed |
| EP-4117629-B1 | COMPOSITIONS AND MEDICAL USE OF NALOXONE | PURDUE PHARMA LP (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260092035-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC (CA) | 2026-04-02 | — | — | US | disclosed |
| US-20260083703-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC (CA) | 2026-03-26 | — | — | US | disclosed |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2026-01-20 | — | — | US | disclosed |
| US-20250388611-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA, INC. (CA) | 2025-12-25 | — | — | US | disclosed |
| US-20250361233-A1 | Compounds For Activating Serotonin Receptor | Psylo Pty Ltd (AU) | 2025-11-27 | — | — | US | disclosed |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2025-11-25 | — | — | US | disclosed |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250353827-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC (CA) | 2025-11-20 | — | — | US | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12415804-B2 | Compounds for activating a serotonin receptor | Psylo Pty Ltd (AU) | 2025-09-16 | — | — | US | disclosed |
| US-12403177-B2 | Silk-based product formulations and methods of use | COCOON BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250257034-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC (CA) | 2025-08-14 | — | — | US | disclosed |
| US-20250250256-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2025-08-07 | — | — | US | disclosed |
| US-12378266-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2025-07-31 | — | — | US | disclosed |
| US-12357573-B2 | Pharmaceutical composition for drug delivery | OREXO AB (SE) | 2025-07-15 | — | — | US | disclosed |
| EP-4581028-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2025-07-09 | — | — | EP | disclosed |
| EP-4581018-A1 | INDAZOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2025-07-09 | — | — | EP | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025129358-A1 | STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES | INTELGENX CORP. (CA) | 2025-06-26 | — | — | WO | disclosed |
| US-20250206739-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-06-26 | — | — | US | disclosed |
| CN-120202186-A | 3-Ethylamino-indole dimers as serotonergic agents for the treatment of diseases associated therewith | 思维模式制药公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025118034-A1 | COMPOUNDS ACTIVE AT THE SEROTONERGIC 5-HT2A RECEPTOR | Psylo Pty Ltd (AU) | 2025-06-12 | — | — | WO | disclosed |
| EP-4565578-A1 | 3-PYRROLIDINE-INDOLE DIMERS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2025-06-11 | — | — | EP | disclosed |
| CN-120091999-A | 3-Pyrrolidine-indole dimers as serotonergic agents for the treatment of related disorders | 思维模式制药公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025104490-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2025-05-22 | — | — | WO | disclosed |
| US-20250163044-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-05-22 | — | — | US | disclosed |
| EP-4532462-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-04-09 | — | — | EP | disclosed |
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| US-12251380-B2 | Depot systems comprising cariprazine or salts thereof | MAPI PHARMA LTD. (IL) | 2025-03-18 | — | — | US | disclosed |
| US-20250074873-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| CN-119546591-A | Indoline derivatives as serotonergic agents for the treatment of related disorders | 思维模式制药公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4511360-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511369-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2025-02-26 | — | — | EP | disclosed |
| CN-119522212-A | Indoline derivatives as serotonergic agents for the treatment of related disorders | 思维模式制药公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250034106-A1 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2025-01-30 | — | — | US | disclosed |
| CN-119384406-A | Compounds of formula (I) | 赛洛私人有限公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4493274-A1 | DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF | Mapi Pharma Ltd. (IL) | 2025-01-22 | — | — | EP | disclosed |
| WO-2025000051-A1 | PYRROLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF MENTAL ILLNESSES | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| US-20240383850-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-11-21 | — | — | US | disclosed |
| CN-118974044-A | Compounds of formula (I) | 赛洛私人有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| EP-4452979-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452937-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452938-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| US-20240352079-A1 | Silk-Based Products, Formulations, and Methods of Use | COCOON BIOTECH INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240350483-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2024-10-24 | — | — | US | disclosed |
| US-20240336641-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2024-10-10 | — | — | US | disclosed |
| CN-118715204-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240317782-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2024-09-26 | — | — | US | disclosed |
| CN-118696029-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240307220-A1 | Combination Therapy to Treat Temperature Sensitive Mutant Tumors | NATIONAL INSTITUTES OF HEALTH | 2024-09-19 | — | — | US | disclosed |
| US-12054504-B2 | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2024-08-06 | — | — | US | disclosed |
| US-12054505-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2024-08-06 | — | — | US | disclosed |
| US-20240238280-A1 | DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF | MAPI PHARMA LTD. (IL) | 2024-07-18 | — | — | US | disclosed |
| US-20240165103-A1 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | PURDUE PHARMA LP (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240166599-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-05-23 | — | — | US | disclosed |
| US-20240166630-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-05-23 | — | — | US | disclosed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240108584-A1 | POLYMERIC MICROPARTICLES, COMPOSITIONS, AND METHODS FOR SUSTAINED RELEASE OF AN ACTIVE AGENT SUSCEPTIBLE TO ABUSE | OHIO STATE INNOVATION FOUNDATION | 2024-04-04 | — | — | US | disclosed |
| US-11931357-B2 | Depot systems comprising Cariprazine or salts thereof | MAPI PHARMA LTD. (IL) | 2024-03-19 | — | — | US | disclosed |
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2024044848-A1 | INDAZOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024044847-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-03-07 | — | — | WO | disclosed |
| US-20240051978-A1 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2024-02-15 | — | — | US | disclosed |
| WO-2024026573-A1 | 3-ETHYLAMINO-INDOLE DIMERS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024026574-A1 | 3-PYRROLIDINE-INDOLE DIMERS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-02-08 | — | — | WO | disclosed |
| US-20240024244-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2024-01-25 | — | — | US | disclosed |
| EP-4301730-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2024-01-10 | — | — | EP | disclosed |
| EP-4301747-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2024-01-10 | — | — | EP | disclosed |
| US-11865112-B2 | Compositions and methods for opioid antagonist delivery | PURDUE PHARMA L.P. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11857547-B2 | Compositions and methods for opioid antagonist delivery | PURDUE PHARMA L.P. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
| EP-4284369-A1 | POLYMERIC MICROPARTICLES, COMPOSITIONS, AND METHODS FOR SUSTAINED RELEASE OF AN ACTIVE AGENT SUSCEPTIBLE TO ABUSE | Ohio State Innovation Foundation (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023201423-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023201421-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4255913-A1 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Mindset Pharma Inc. (CA) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023175598-A1 | DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF | MAPI PHARMA LTD. (IL) | 2023-09-21 | — | — | WO | disclosed |
| US-20230293515-A1 | DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF | MAPI PHARMA LTD. (IL) | 2023-09-21 | — | — | US | disclosed |
| CN-116710083-A | Compositions and methods for treating metabolic disorders | 反应IP控股有限责任公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230270741-A1 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | PURDUE PHARMA LP (US) | 2023-08-31 | — | — | US | disclosed |
| US-11737980-B2 | Pharmaceutical composition for drug delivery | OREXO AB (SE) | 2023-08-29 | — | — | US | disclosed |
| US-20230263859-A1 | SILK-BASED PRODUCT FORMULATIONS AND METHODS OF USE | COCOON BIOTECH, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115167-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115165-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4196122-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-01 | — | — | US | disclosed |
| US-11633455-B2 | Silk-based product formulations and methods of use | COCOON BIOTECH INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230118872-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-04-20 | — | — | US | disclosed |
| CN-115974757-A | Silodosin derivatives as serotonergic hallucinogens for the treatment of CNS disorders | 明德赛特制药公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20230105399-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-04-06 | — | — | US | disclosed |
| US-20230095235-A1 | COMPOSITIONS AND METHODS FOR NALOXONE DELIVERY | PURDUE PHARMA L.P. | 2023-03-30 | — | — | US | disclosed |
| EP-4154866-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2023-03-29 | — | — | EP | disclosed |
| US-20230093302-A1 | A NOVEL MAO-B INHIBITOR DRG-MAOB-1 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | BAHCESEHIR UNIVERSITESI (TR) | 2023-03-23 | — | — | US | disclosed |
| US-20230088611-A1 | A NOVEL SELECTIVE MAO-B INHIBITOR DRG-MAOB-2 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | ISTANBUL GEDIK UNIVERSITESI | 2023-03-23 | — | — | US | disclosed |
| US-11597738-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2023-03-07 | — | — | US | disclosed |
| US-11591353-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2023-02-28 | — | — | US | disclosed |
| WO-2023019366-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023019368-A1 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023019367-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| EP-4117629-A1 | COMPOSITIONS AND METHODS FOR NALOXONE DELIVERY | Purdue Pharma L.P. (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-4100390-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Mindset Pharma Inc. (CA) | 2022-12-14 | — | — | EP | disclosed |
| EP-4100391-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Mindset Pharma Inc. (CA) | 2022-12-14 | — | — | EP | disclosed |
| EP-4100403-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Mindset Pharma Inc. (CA) | 2022-12-14 | — | — | EP | disclosed |
| CN-115427395-A | Silodosin derivatives as serotonergic hallucinogens for the treatment of CNS disorders | 明德赛特制药公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-115397810-A | Silodosin derivatives as serotonergic hallucinogens for the treatment of CNS disorders | 明德赛特制药公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115380028-A | 3-pyrrolidine-indole derivatives as serotonergic hallucinogens for the treatment of CNS disorders | 明德赛特制药公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220362241-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220324889-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-10-13 | — | — | US | disclosed |
| US-11453689-B2 | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2022-09-27 | — | — | US | disclosed |
| US-11446353-B2 | Compositions and methods for the treatment of fungal infections | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220289774-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-09-15 | — | — | US | disclosed |
| US-20220290237-A1 | METHOD FOR PREDICTING THE RESPONSE OF ANTIPSYCHOTIC DRUGS | UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE (FR) | 2022-09-15 | — | — | US | disclosed |
| WO-2022183287-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022183288-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022187839-A1 | COMBINATION THERAPY TO TREAT TEMPERATURE SENSTIVE MUTANT TUMORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-11427604-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2022-08-30 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2022165352-A1 | POLYMERIC MICROPARTICLES, COMPOSITIONS, AND METHODS FOR SUSTAINED RELEASE OF AN ACTIVE AGENT SUSCEPTIBLE TO ABUSE | OHIO STATE INNOVATION FOUNDATION (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-4034119-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022120475-A1 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-06-16 | — | — | WO | disclosed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220087938-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2022-03-24 | — | — | US | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3959340-A1 | METHOD FOR PREDICTING THE RESPONSE OF ANTIPSYCHOTIC DRUGS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-03-02 | — | — | EP | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-01-27 | — | — | US | disclosed |
| US-20220017549-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-01-20 | — | — | US | disclosed |
| US-20220017550-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-01-20 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2021234366-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021183303-A1 | COMPOSITIONS AND METHODS FOR NALOXONE DELIVERY | PURDUE PHARMA L. P. (US) | 2021-09-16 | — | — | WO | disclosed |
| EP-3876938-A1 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | Purdue Pharma L.P. (US) | 2021-09-15 | — | — | EP | disclosed |
| WO-2021155470-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021155467-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021155468-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2021-08-12 | — | — | WO | disclosed |
| US-20210228684-A1 | SILK-BASED PRODUCT FORMULATIONS AND METHODS OF USE | COCOON BIOTECH INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210228570-A1 | COMPOSITIONS AND METHODS FOR OPIOID OVERDOSE RESCUE | PURDUE PHARMA LP (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210228591-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | WASHINGTON UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
| US-20210138071-A1 | SILK-BASED PRODUCTS AND METHODS OF USE | COCOON BIOTECH INC. | 2021-05-13 | — | — | US | disclosed |
| EP-3801625-A1 | SILK-BASED PRODUCT FORMULATIONS AND METHODS OF USE | Cocoon Biotech Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021062307-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2020247594-A1 | SILK-BASED PRODUCTS, FORMULATIONS, AND METHODS OF USE | COCOON BIOTECH INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020216832-A1 | METHOD FOR PREDICTING THE RESPONSE OF ANTIPSYCHOTIC DRUGS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020201768-A1 | PHARMACEUTICAL COMPOSITIONS | OREXO AB (SE) | 2020-10-08 | — | — | WO | disclosed |
| US-20200138805-A1 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | PURDUE PHARMA L.P. | 2020-05-07 | — | — | US | disclosed |
| WO-2020007898-A1 | METHODS AND COMPOSITIONS FOR TREATING BRAIN INJURY OR NEURODEGENERATIVE DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-09 | — | — | WO | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2019204764-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | WASHINGTON UNIVERSITY (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2018015915-A1 | A PARENTERAL CONTROLLED RELEASE COMPOSITION OF AN ATYPICAL ANTIPSYCHOTIC AGENT | CADILA HEALTHCARE LIMITED (IN) | 2018-01-25 | — | — | WO | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160361311-A1 | LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN | American University of Cairo (EG) | 2016-12-15 | — | — | US | disclosed |
| US-20160361311-A1 | LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN | American University of Cairo (EG) | 2016-12-15 | — | — | US | disclosed |
| CN-105879031-A | Anticancer-drug-free composition realizing synergistic treatment on tumor | 北京大学 | 2016-08-24 | — | — | CN | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140350081-A1 | INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | US ARMY, SECRETARY OF THE ARMY | 2014-11-27 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2013070107-A1 | 5H-DIBENZO[B,E][1,4]DIAZEPINE DERIVATIVES AND USE THEREOF | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТЕК" (RU) | 2013-05-16 | — | — | WO | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7998971-B2 | 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection | BRAINCELLS INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7985756-B2 | Modulation of neurogenesis by PDE inhibition | BRAINCELLS INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| WO-2011063115-A1 | COMBINATION OF NOOTROPIC AGENT WITH ONE OR MORE NEUROGENIC OR NEUROGENIC SENSITIZING AGENTS FOR STIMULATING OR INCREASING NEUROGENESIS | BRAINCELLS INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| EP-2314289-A1 | Gaba receptor mediated modulation of neurogenesis | Braincells, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| CN-102037015-A | Inhibition of angiogenesis | GENENTECH INC | 2011-04-27 | — | — | CN | disclosed |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| CN-102018715-A | Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier | PHILADELPHIA HEALTH & EDUCATIO | 2011-04-20 | — | — | CN | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2275095-A2 | Neurogenesis by muscarinic receptor modulation | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2275096-A2 | Neurogenesis via modulation of the muscarinic receptors | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2258359-A2 | Neurogenesis by muscarinic receptor modulation with sabcomelin | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258357-A2 | Neurogenesis with acetylcholinesterase inhibitor | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258358-A2 | Neurogenesis with acetylcholinesterase inhibitor | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| WO-2010099217-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | BRAINCELLS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216734-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216805-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | BRAINCELLS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20100120842-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7678808-B2 | 5 HT receptor mediated neurogenesis | BRAINCELLS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678363-B2 | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs | BRAINCELLS INC (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090325949-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2125017-A2 | MODULATION OF NEUROGENESIS WITH USE OF MODAFINIL | Braincells, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-101563083-A | Combinations containing a 4-acylaminopyridine derivative | BRAINCELLS INC (US) | 2009-10-21 | — | — | CN | disclosed |
| CN-101500611-A | Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-08-05 | — | — | CN | disclosed |
| EP-2076288-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2068872-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | Braincells, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2066355-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2026813-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | Braincells, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-2021000-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | Braincells, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| EP-1991212-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | Braincells, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| CN-101309682-A | Modulation of neurogenesis by pde inhibition | BRAINCELLS INC (US) | 2008-11-19 | — | — | CN | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| JP-2008206937-A | DOUBLE CLOTHEPIN | SUGIURA TAKESHI | 2008-09-11 | — | — | JP | disclosed |
| JP-2008206937-A | DOUBLE CLOTHEPIN | SUGIURA TAKESHI | 2008-09-11 | — | — | JP | disclosed |
| WO-2008097861-A2 | MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS | BRAINCELLS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080188457-A1 | Modulation of Neurogenesis with Biguanides and GSK3-beta Agents | BRAINCELLS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080171750-A1 | Modulation Of Neurogenesis With Use of Modafinil | BRAINCELLS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008086483-A2 | MODULATION OF NEUROGENESIS WITH USE OF MODAFINIL | BRAINCELLS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-1942879-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | Braincells, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1476151-B1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORGANON NV (NL) | 2008-07-16 | — | — | EP | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008083204-A2 | MODULATION OF NEUROGENESIS BY MELATONINERGIC LIGANDS | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1940389-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | Braincells, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1937236-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | Braincells, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1928437-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | Braincells, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080108574-A1 | MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008039863-A2 | COMPOSITION COMPRISING A MELANOCORTIN RECEPTOR (MCR) MODULATING AGENT ALONE OR IN COMBINATION WITH A SECOND NEUROGENIC AGENT FOR TREATING NERVOUS SYSTEM DISORDERS | BRAINCELLS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008036678-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036846-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2008030651-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | BRAINCELLS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080064671-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | BRAINCELLS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| CN-101119715-A | SPM 927 for add-on therapy of schizophrenia | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-02-06 | — | — | CN | disclosed |
| CN-101094674-A | Use of n-desmethylclozapine to treat human neuropsychiatric disease | ACADIA PHARM INC (US) | 2007-12-26 | — | — | CN | disclosed |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134077-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1841417-A2 | SPM 927 FOR ADD-ON THERAPY OF SCHIZOPHRENIA | SCHWARZ PHARMA AG (DE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060252749-A1 | Lacosamide for add-on therapy of psychosis | SRZ PROPERTIES, INC. (US) | 2006-11-09 | — | — | US | disclosed |
| WO-2006079547-A2 | SPM 927 FOR ADD-ON THERAPY OF SCHIZOPHRENIA | SCHWARZ PHARMA AG (DE) | 2006-08-03 | — | — | WO | disclosed |
| CN-1264848-C | Pyrrolo [2, 1-b ] [1,3] benzothiazanes * and their use for the preparation of medicaments with antipsychotic activity | SIGMA TAU IND FARMACEUTI (IT) | 2006-07-19 | — | — | CN | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| CN-1674879-A | Immunomodulation and effects on cellular processes involving serotonin family receptors and the blood brain barrier | PHILADELPHIA HEALTH & EDUCATIO (US) | 2005-09-28 | — | — | CN | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
| EP-1307463-B1 | PYRROLO 2,1-B]-[1,3]BENZOTHIAZEPINES AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS WITH ANTIPSYCHOTIC ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2005-01-26 | — | — | EP | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| EP-1476151-A1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Akzo Nobel N.V. (NL) | 2004-11-17 | — | — | EP | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6710041-B2 | Pyrrolo[2,1-B][3,1] benzothiazepines and their use for the preparation of medicaments with antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-03-23 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20030186959-A1 | Pyrrolo[2,1-b][3,1] benzothiazepines and their use for the preparation of medicaments with antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-10-02 | — | — | US | disclosed |
| CN-1444588-A | Pyrrolo[2,1-b] [1,3] benzothiazepines and their use for preparation of medicaments with antipsychotic activity | SIGMA TAU IND FARMACEUTI (IT) | 2003-09-24 | — | — | CN | disclosed |
| WO-2003068220-A1 | 1-ARYLSULFONYL-3-SUBSTITUTED INDOLE AND INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | AKZO NOBEL N.V. (NL) | 2003-08-21 | — | — | WO | disclosed |
| EP-1307463-A1 | PYRROLO 2,1-B]-[1,3]BENZOTHIAZEPINES AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS WITH ANTIPSYCHOTIC ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2003-05-07 | — | — | EP | disclosed |
| EP-1100803-B1 | PYRROLO [2,1-B] [1,3]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2002-10-02 | — | — | EP | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6391870-B2 | DOPAMINERGIC AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-05-21 | — | — | US | disclosed |
| WO-2002010175-A1 | PYRROLO[2,1-b][1,3]BENZOTHIAZEPINES AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS WITH ANTIPSYCHOTIC ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-02-07 | — | — | WO | disclosed |
| US-20020006921-A1 | Pyrrolo {2,1-b}{1,3}benzothiazepines with atypical antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-01-17 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
| JP-H0871293-A | CLOTHESPIN WITH ROLLER | AOKI NAOYUKI | 1996-03-19 | — | — | JP | disclosed |
| US-5179768-A | Clothespin | JIO CHAIN FOU (TW) | 1993-01-19 | — | — | US | disclosed |
| US-5179768-A | Clothespin | JIO CHAIN FOU (TW) | 1993-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR5A, TPH2 | DRD2 55/4885HRH1 469/4885HTR2C 8/4885 |
| US-20080188457-A1 | Modulation of Neurogenesis with Biguanides and GSK3-beta Agents | PYGB, DCX, GSK3B | DRD2 3056/4885HRH1 4858/4885HTR2C 1856/4885 |
| US-20250206739-A1 | Compounds | NLN, SLC18A2, PYGB | DRD2 226/4885HRH1 2945/4885HTR2C 23/4885 |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | DRD2 1528/4885HRH1 1826/4885HTR2C 660/4885 |
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | DRD2 4644/4885HRH1 2287/4885HTR2C 4473/4885 |
| US-12415804-B2 | Compounds for activating a serotonin receptor | HTR2C, HTR6, HTR2A | DRD2 96/4885HRH1 515/4885HTR2C 1/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | DRD2 1115/4885HRH1 2595/4885HTR2C 787/4885 |
| US-20220324889-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | DRD2 29/4885HRH1 440/4885HTR2C 7/4885 |
| US-20100120842-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | DRD2 1528/4885HRH1 1826/4885HTR2C 660/4885 |
| US-20080108574-A1 | MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | MC1R, MC3R, MC5R | DRD2 1472/4885HRH1 2169/4885HTR2C 344/4885 |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | HMGCR, DCX, SREBF1 | DRD2 4422/4885HRH1 3466/4885HTR2C 3519/4885 |
| US-20030186959-A1 | Pyrrolo[2,1-b][3,1] benzothiazepines and their use for the preparation of medicaments with antipsychotic activity | TPH1, GRIN2C, GRIN2B | DRD2 48/4885HRH1 1639/4885HTR2C 155/4885 |
| US-20140350081-A1 | INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | DDT, ADRA2C, MCHR1 | DRD2 6/4885HRH1 36/4885HTR2C 29/4885 |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR5A, HTR6, GAP43 | DRD2 232/4885HRH1 1338/4885HTR2C 10/4885 |
| US-20240166599-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, TPH2, HTR3A | DRD2 188/4885HRH1 916/4885HTR2C 10/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | DRD2 242/4885HRH1 1427/4885HTR2C 16/4885 |
| US-20220017550-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR3A, TPH1, HTR5A | DRD2 37/4885HRH1 413/4885HTR2C 6/4885 |
| US-20240336641-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR3A, TPH1, HTR5A | DRD2 37/4885HRH1 413/4885HTR2C 6/4885 |
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | DRD2 226/4885HRH1 2945/4885HTR2C 23/4885 |
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | DRD2 226/4885HRH1 2945/4885HTR2C 23/4885 |
| US-20250250256-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, TPH2, HTR5A | DRD2 180/4885HRH1 906/4885HTR2C 9/4885 |
| US-20230118872-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | DRD2 29/4885HRH1 440/4885HTR2C 7/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | DRD2 4305/4885HRH1 2960/4885HTR2C 3530/4885 |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | DRD2 2078/4885HRH1 4156/4885HTR2C 1643/4885 |
| US-20160361311-A1 | LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN | CD81, HAVCR2, CTRL | DRD2 2441/4885HRH1 623/4885HTR2C 248/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | DRD2 4801/4885HRH1 2743/4885HTR2C 4370/4885 |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | MAOB, MAOA, ME3 | DRD2 1537/4885HRH1 1951/4885HTR2C 996/4885 |
| US-20250361233-A1 | Compounds For Activating Serotonin Receptor | HTR2C, HTR2A, HTR6 | DRD2 71/4885HRH1 522/4885HTR2C 1/4885 |
| US-20230088611-A1 | A NOVEL SELECTIVE MAO-B INHIBITOR DRG-MAOB-2 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | MAOB, MAOA, HTR2B | DRD2 217/4885HRH1 700/4885HTR2C 43/4885 |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | DRD2 29/4885HRH1 440/4885HTR2C 7/4885 |
| US-12378266-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | DRD2 29/4885HRH1 440/4885HTR2C 7/4885 |
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | SLC5A1, SLC5A2, GLP1R | DRD2 1461/4885HRH1 3021/4885HTR2C 1149/4885 |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | PPARG, PPARA, PPARD | DRD2 2120/4885HRH1 4199/4885HTR2C 1864/4885 |
| US-20250074873-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | DRD2 226/4885HRH1 2945/4885HTR2C 23/4885 |
| US-12054505-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | DRD2 29/4885HRH1 440/4885HTR2C 7/4885 |
| US-11453689-B2 | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR3A, TPH1, HTR5A | DRD2 37/4885HRH1 413/4885HTR2C 6/4885 |
| US-11597738-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | DRD2 29/4885HRH1 440/4885HTR2C 7/4885 |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | DRD2 29/4885HRH1 440/4885HTR2C 7/4885 |
| US-20250353827-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, TPH2, HTR5A | DRD2 45/4885HRH1 425/4885HTR2C 8/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | DRD2 2243/4885HRH1 4297/4885HTR2C 1871/4885 |
| US-20090325949-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR5A, HTR6, GAP43 | DRD2 232/4885HRH1 1338/4885HTR2C 10/4885 |
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | DRD2 536/4885HRH1 2861/4885HTR2C 94/4885 |
| US-20240238280-A1 | DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF | MC2R, CRHR1, MC5R | DRD2 93/4885HRH1 2772/4885HTR2C 300/4885 |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | DRD2 1521/4885HRH1 4322/4885HTR2C 1496/4885 |
| US-12054504-B2 | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR3A, TPH1, HTR5A | DRD2 37/4885HRH1 413/4885HTR2C 6/4885 |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | DRD2 2850/4885HRH1 3969/4885HTR2C 1738/4885 |
| US-20240383850-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR5A, TPH2 | DRD2 51/4885HRH1 443/4885HTR2C 8/4885 |
| US-11591353-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | DRD2 29/4885HRH1 440/4885HTR2C 7/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | DRD2 345/4885HRH1 294/4885HTR2C 5/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | DRD2 226/4885HRH1 2945/4885HTR2C 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.